Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-25 | Peter S. García, M.B.A. has served on our Board of Directors since December 2021. ... At the end of the last fiscal year, the Audit Committee was composed of the following directors: Simon X. Benito, Peter S. Garcia, David R. Hoffmann, Gail J. Maderis and Judy J. Robertson. |
| 2023-04-27 | Peter S. Garcia, M.B.A. has served on our Board of Directors since December 2021. ... At the end of the last fiscal year, the Compensation Committee was composed of Mohammad Azab, Peter S. Garcia, David R. Hoffmann and Gail J. Maderis. ... At the end of the last fiscal year, the Audit Committee was composed of the following directors: Peter S. Garcia, David R. Hoffmann, Gail J. Maderis and Judy J. Robertson. ... Director Compensation for Fiscal 2022: Peter S. Garcia, M.B.A. Fees Earned or Paid in Cash ($) 49,783, Option Awards ($) 23,150, Total ($) 72,933. |
| 2024-08-12 | Peter S. Garcia, M.B.A. has served on our Board of Directors since December 2021. Mr. Garcia has worked as a Chief Financial Officer in the life sciences industry for over 25 years. Mr. Garcia’s pharmaceutical industry experience relating to finance and accounting, executive management, treasury, employee benefits and audit matters are among the qualifications he brings to our Board of Directors. Director Compensation for Fiscal 2023 shows cash fees of $61,613 and option awards valued at $23,115, totaling $84,728. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22